Photo of a simulated printing of a human ear using Collplant’s bio-ink..
(photo credit: Courtesy)
The Israeli regenerative medicine company CollPlant has filed a US patent application for “biological ink” to be used in the three-dimensional printing of tissues and organs.
CollPlant’s patent application refers to formulations of bio-ink based on the firm’s rhCollagen (recombinant type 1 human collage), a plant-based technology that mimics human collagen – the main structural protein in connective tissues. By filing the patent, the Ness Ziona-based company expressed hopes of establishing its position as a leader in three-dimensional biological printing and of forming partnerships in the field of organ printing.
“We are promoting commercial collaborations with leading international companies in the field of 3D bio-printing of tissue and organ, with the aim of taking part in providing a solution to the significant need for life saving organs,” said Yehiel Tal, CEO of CollPlant. “This market need represents high economic potential for the company.”
CollPlant’s bio-ink enables the printing of three-dimensional scaffolds combined with human cells and/or growth factors, as a basis for tissue or organ generation, a statement from the company explained. In addition to making use of collagen, the ink formulations can also include other proteins and polymers that are compatible with various printing technologies and printed organ characteristics.
“The new patent establishes CollPlant’s technology status in 3D biological printing, creates barriers to entry for competitors and increases the trust of potential partners,” Tal said. “CollPlant’s technology is highly regarded by major international players, and our objective is to enter into our first significant collaboration this year.”